Losartan Potatssium
Product Images NDC 58517-240

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potatssium (NDC 58517-240). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by New Horizon Rx Group, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

3457501e-figure-01 (3457501e Figure 01)

Chemical structure of Losartan Potassium, illustrating the molecular arrangement of its atoms including the chlorinated pyrimidine ring, biphenyl group, and potassium ion.*

FDA Label Image

3457501e-figure-02 (3457501e Figure 02)

A line graph comparing the percentage of patients with primary endpoint over study months for Losartan Potassium and Atenolol. The x-axis shows study months from 0 to 66, and the y-axis shows the percentage from 0 to 16%. Losartan Potassium is represented by a solid line and Atenolol by a dashed line. An adjusted risk reduction of 13% with p=0.021 is noted below the graph.*

FDA Label Image

3457501e-figure-03 (3457501e Figure 03)

A line graph comparing the percentage of patients with fatal or non-fatal stroke over a study period of up to 66 months for two treatments: Atenolol (dashed line) and Losartan Potassium (solid line). The graph shows the adjusted risk reduction of 25% with Losartan Potassium, with statistical significance indicated by p=0.001.*

FDA Label Image

3457501e-figure-04 (3457501e Figure 04)

A forest plot chart comparing the hazard ratios of Losartan Potassium (Losartan-K) versus Atenolol for primary composite events and fatal/non-fatal strokes across different patient subgroups including age, gender, race, ischemic stroke history, diabetes, and cardiovascular disease history. The chart displays event rates, hazard ratios with 95% confidence intervals, and indicates which drug is favored in each subgroup.*

FDA Label Image

3457501e-figure-05 (3457501e Figure 05)

A line graph comparing the percentage of patients with an event over 48 months between losartan potassium tablet and placebo groups. The y-axis represents % patients with event, the x-axis shows time in months, and the graph indicates a 16.1% risk reduction with losartan potassium (p=0.022).*

FDA Label Image

3457501e-figure-06 (3457501e Figure 06)

Label for Losartan Potassium Tablets, USP 50 mg, with 30 tablets per bottle. The label includes storage instructions, the New Horizon Rx Group, LLC as labeler, and manufacturing by Cadila Healthcare Ltd. It features the NDC number 58517-240-30 and includes the New Horizon Rx logo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.